Affimed N.V.

DB:A28A Stock Report

Market Cap: €39.8m

Affimed Valuation

Is A28A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A28A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A28A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A28A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A28A?

Key metric: As A28A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A28A. This is calculated by dividing A28A's market cap by their current revenue.
What is A28A's PS Ratio?
PS Ratio7x
Sales€5.64m
Market Cap€39.75m

Price to Sales Ratio vs Peers

How does A28A's PS Ratio compare to its peers?

The above table shows the PS ratio for A28A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
MDG1 Medigene
3x16.1%€22.6m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
2INV 2invest
8.2xn/a€63.8m
CNW co.don
0.7xn/a€6.5m
A28A Affimed
7x66.3%€41.4m

Price-To-Sales vs Peers: A28A is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does A28A's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
A28A 7.0xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A28A is good value based on its Price-To-Sales Ratio (7x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is A28A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A28A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7x
Fair PS Ratio17.3x

Price-To-Sales vs Fair Ratio: A28A is good value based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (17.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A28A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.49
€26.74
+973.9%
52.5%€55.12€9.48n/a7
Nov ’25€2.78
€27.95
+905.3%
53.5%€55.12€9.01n/a7
Oct ’25€2.93
€27.95
+853.9%
53.5%€55.12€9.01n/a7
Sep ’25€3.94
€28.29
+618.0%
53.1%€55.12€9.29n/a7
Aug ’25€4.57
€28.29
+519.0%
53.1%€55.12€9.29n/a7
Jul ’25€4.96
€28.29
+470.4%
53.1%€55.12€9.29n/a7
Jun ’25€3.67
€27.13
+639.2%
58.8%€55.64€9.31n/a7
May ’25€5.06
€27.78
+449.0%
61.7%€55.64€9.31n/a6
Apr ’25€4.83
€35.48
+634.7%
59.5%€64.63€9.31n/a6
Mar ’25€5.71
€53.86
+843.2%
64.8%€120.47€9.27n/a6
Feb ’25€5.01
€52.31
+945.1%
66.9%€120.47€9.27n/a6
Jan ’25€4.76
€52.31
+997.9%
66.9%€120.47€9.27n/a6
Dec ’24€4.03
€52.57
+1,205.0%
61.2%€119.78€9.21n/a7
Nov ’24€3.42
€55.32
+1,517.6%
52.9%€118.60€9.08€2.788
Oct ’24€4.52
€55.26
+1,121.4%
50.0%€118.60€9.08€2.939
Sep ’24€4.93
€54.85
+1,013.1%
50.3%€118.60€9.08€3.949
Aug ’24€5.26
€58.90
+1,019.8%
47.9%€121.63€9.28€4.579
Jul ’24€5.60
€59.11
+955.5%
47.8%€121.63€9.28€4.969
Jun ’24€8.08
€60.98
+654.8%
45.2%€121.46€9.28€3.679
May ’24€8.20
€67.88
+727.8%
41.4%€119.35€9.18€5.069
Apr ’24€6.67
€68.41
+925.9%
41.5%€119.35€9.18€4.839
Mar ’24€8.81
€71.70
+713.6%
38.9%€123.49€19.00€5.7110
Feb ’24€11.19
€75.58
+575.3%
38.9%€123.49€19.00€5.0110
Jan ’24€11.26
€75.87
+573.9%
38.7%€123.49€19.00€4.7610
Dec ’23€20.07
€92.98
+363.4%
37.5%€154.02€19.23€4.039
Nov ’23€17.70
€97.40
+450.3%
37.2%€154.94€20.46€3.429

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%